Studies
What research shows about hPG80, explained simply, with published references.
Understanding hPG80· 4 min readWho is behind this test?
More than 10 years of French research
Read the article →
Clinical studies· 5 min readNorway: the experience of a private clinic
24 people with no symptoms, three level ranges and around four years of medical follow-up.
Read the article →
Clinical studies· 5 min readMore than 4,000 patients: what the hPG80 studies show
26 clinical studies, 4,045 patient samples and 1,199 samples from healthy volunteers.
Read the article →
Clinical studies· 4 min readhPG80 and prognosis: understanding the observed associations
In people already receiving care for cancer, high hPG80 levels are associated with less favourable clinical outcomes. A statistical association does not predict an individual's course.
Read the article →
Understanding hPG80· 4 min readHow does hPG80 work?
A circulating protein measured in the blood, whose level is always interpreted by a doctor.
Read the article →
Risk factors· 2 min readSmoking and hPG80: what you need to know
Smoking raises the level. After quitting smoking, the level may return to the low range within the following month.
Read the article →
Prevonco is currently available in France only.
An aid to the early detection of 16 cancers
No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.
Pre-register for free →Sources
- 1.biodena.care
- 2.You et al., « The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients », EBioMedicine, 2020 ; 51 : 102574
- 3.Berntsen et al., « Evaluation of hPG80 (Circulating Progastrin) As a Multi-Cancer Early Detection (MCED) Test In a Private Clinic in Norway », Annals of Case Reports, 2025, 10 : 2328
- 4.You et al., « Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study », Biomarker Research, 2025 — NCT03787056
- 5.Kohli et al., « Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma », Cancers, 2021
- 6.Dupuy et al., « Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma », Cancers, 2022
- 7.Prieur et al., « Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort », BMC Cancer, 2023
- 8.Vire et al., Biomarker Research, 2025